This is a great buying opportunity. Target price is over 60. Where else can we get a 20 % return this year?
OK, so revenues have fallen every quarter for about eight straight years now and you call this company a "buying opportunity"? Newsflash: If you had purchased this awful stock twelve years ago, you'd still be trying to break even. There are only so many heads you can chop and buildings you can shutter. Merck is running out of costs to cut and the pressure is on to stop raising prices. I wouldn'y buy this stock at $25 per share.
Guess people are buying mrk for the dividend. Market is up and mrk is still down. Must not be a lot of confidence in the pipeline. Merger seems like only solution.